(ignored: NYSTATIN) Metronidazole was listed in the December 27, 2023 extract; the same DIN 00545066 is listed as Apo-Metronidazole Tablets in the current extract (September 22, 2026). This is not an absent DIN. Source: odb-formulary-ed43-extract-2023-12-27.xml; odb-formulary-ed43-extract-2026-09-22.xml.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Apo-metronidazole tablets (metronidazole) and other metronidazole products
Metronidazole
Form:
15 of 15 products shown
11 general benefit · 4 not a benefit
Apo-Metronidazole Tablets · DIN 00545066 · 250 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Metronidazole Tablets · DIN 00545066
Manufacturer: Apotex Inc.; listing date 1996-10-01
Daily cost (source): $0.1716
Health Canada: Marketed since 2024-05-22 · brand APO-METRONIDAZOLE TABLETS · ATC P01AB01 METRONIDAZOLE · form Tablet · route Oral · ingredients METRONIDAZOLE 250 MG · company Apotex inc · schedule Prescription
Apo-Metronidazole Tablets: Formulary list price $0.06 per unit (the source does not state the unit; exact figure $0.0572). What the ministry pays, not the patient.
DIN 00545066: Apo-Metronidazole Tablets
Raw flags: sec3=Y
Item: 083200001; group id 125; item number 0210; lccId None; manufacturer id APX
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.0572; ministry $0.0572
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00545066
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4902Interchangeable products
Flagyl · DIN 01926896 · not recorded
Mint-Metronidazole · DIN 02535807 · $0.0572
Shortage status: resolved shortage (ended October 15, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00545066
Shortage record checked October 6, 2026
Noritate · DIN 02156091 · 1% · Top Cr
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Noritate · DIN 02156091
Manufacturer: Valeant Canada Ltd.; listing date 1997-04-10
Health Canada: Marketed since 2019-05-07 · brand NORITATE · ATC D06BX01 METRONIDAZOLE · form Cream · route Topical · ingredients METRONIDAZOLE 1 %/W/W · company Bausch health, canada inc. · schedule Prescription
DIN 02156091: Noritate
Raw flags: sec3=Y
Item: 840416037; group id 830; item number 2019; lccId None; manufacturer id VAL
Source form: Top Cr; strength: 1%
Recorded listing: General benefit
Source prices (unrounded): $0.8149; ministry $0.8149
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02156091
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19257
Shortage status: avoided shortage; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02156091
Shortage record checked October 6, 2026
Metrogel · DIN 02297809 · 1% · Top Gel
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Metrogel · DIN 02297809
Manufacturer: Galderma Canada Inc; listing date 2010-03-02
Health Canada: Marketed since 2007-12-20 · brand METROGEL 1% · ATC D06BX01 METRONIDAZOLE · form Gel · route Topical · ingredients METRONIDAZOLE 1 % · company Galderma canada inc. · schedule Prescription
DIN 02297809: Metrogel
Raw flags: sec3=Y
Item: 840416043; group id 830; item number 2021; lccId None; manufacturer id GAC
Source form: Top Gel; strength: 1%
Recorded listing: General benefit
Source prices (unrounded): $0.7235; ministry $0.7235
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02297809
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78314
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02297809
Shortage record checked October 6, 2026
Mint-Metronidazole · DIN 02535807 · 250 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Mint-Metronidazole · DIN 02535807
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-10-31
Daily cost (source): $0.1716
Health Canada: Marketed since 2023-09-07 · brand MINT-METRONIDAZOLE · ATC P01AB01 METRONIDAZOLE · form Tablet · route Oral · ingredients METRONIDAZOLE 250 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Metronidazole: Formulary list price $0.06 per unit (the source does not state the unit; exact figure $0.0572). What the ministry pays, not the patient.
DIN 02535807: Mint-Metronidazole
Raw flags: sec3=Y
Item: 083200001; group id 125; item number 0210; lccId None; manufacturer id MIN
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.0572; ministry $0.0572
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02535807
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102463Interchangeable products
Apo-Metronidazole Tablets · DIN 00545066 · $0.0572
Flagyl · DIN 01926896 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02535807
Shortage record checked October 6, 2026
Apo-Metronidazole · DIN 02248562 · 500 mg · capsule
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Metronidazole · DIN 02248562
Manufacturer: Apotex Inc.; listing date 2004-07-20
Daily cost (source): $0.8217
Health Canada: Marketed since 2018-04-26 · brand APO-METRONIDAZOLE · ATC P01AB01 METRONIDAZOLE · form Capsule · route Oral · ingredients METRONIDAZOLE 500 MG · company Apotex inc · schedule Prescription
Apo-Metronidazole: Formulary list price $0.27 per unit (the source does not state the unit; exact figure $0.2739). What the ministry pays, not the patient.
DIN 02248562: Apo-Metronidazole
Raw flags: sec3=Y
Item: 083200002; group id 125; item number 0209; lccId None; manufacturer id APX
Source form: Cap; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.2739; ministry $0.2739
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248562
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72917Interchangeable products
Auro-Metronidazole · DIN 02470284 · $0.2739
Flagyl · DIN 01926853 · not recorded
M-Metronidazole · DIN 02519755 · $0.2739
Metronidazole · DIN 02518767 · $0.2739
Metronidazole · DIN 02534592 · $0.2739
PMS-Metronidazole · DIN 00783137 · $0.2739
Shortage status: shortage reported ended August 7, 2026 (report last updated August 7, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248562
Shortage record checked October 6, 2026
Auro-Metronidazole · DIN 02470284 · 500 mg · capsule
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Metronidazole · DIN 02470284
Manufacturer: Auro Pharma Inc.; listing date 2018-07-31
Daily cost (source): $0.8217
Health Canada: Marketed since 2018-04-03 · brand AURO-METRONIDAZOLE · ATC P01AB01 METRONIDAZOLE · form Capsule · route Oral · ingredients METRONIDAZOLE 500 MG · company Auro pharma inc · schedule Prescription
Auro-Metronidazole: Formulary list price $0.27 per unit (the source does not state the unit; exact figure $0.2739). What the ministry pays, not the patient.
DIN 02470284: Auro-Metronidazole
Raw flags: sec3=Y
Item: 083200002; group id 125; item number 0209; lccId None; manufacturer id AUR
Source form: Cap; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.2739; ministry $0.2739
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02470284
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95926Interchangeable products
Apo-Metronidazole · DIN 02248562 · $0.2739
Flagyl · DIN 01926853 · not recorded
M-Metronidazole · DIN 02519755 · $0.2739
Metronidazole · DIN 02518767 · $0.2739
Metronidazole · DIN 02534592 · $0.2739
PMS-Metronidazole · DIN 00783137 · $0.2739
Shortage status: resolved shortage (ended June 24, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02470284
Shortage record checked October 6, 2026
M-Metronidazole · DIN 02519755 · 500 mg · capsule
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
M-Metronidazole · DIN 02519755
Manufacturer: Mantra Pharma Inc.; listing date 2022-04-29
Daily cost (source): $0.8217
Health Canada: Marketed since 2022-03-04 · brand M-METRONIDAZOLE · ATC P01AB01 METRONIDAZOLE · form Capsule · route Oral · ingredients METRONIDAZOLE 500 MG · company Mantra pharma inc · schedule Prescription
M-Metronidazole: Formulary list price $0.27 per unit (the source does not state the unit; exact figure $0.2739). What the ministry pays, not the patient.
DIN 02519755: M-Metronidazole
Raw flags: sec3=Y
Item: 083200002; group id 125; item number 0209; lccId None; manufacturer id MAT
Source form: Cap; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.2739; ministry $0.2739
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02519755
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100899Interchangeable products
Apo-Metronidazole · DIN 02248562 · $0.2739
Auro-Metronidazole · DIN 02470284 · $0.2739
Flagyl · DIN 01926853 · not recorded
Metronidazole · DIN 02518767 · $0.2739
Metronidazole · DIN 02534592 · $0.2739
PMS-Metronidazole · DIN 00783137 · $0.2739
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02519755
Shortage record checked October 6, 2026
Metronidazole · DIN 02518767 · 500 mg · capsule
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Metronidazole · DIN 02518767
Manufacturer: Jamp Pharma Corporation; listing date 2022-06-30
Daily cost (source): $0.8217
Health Canada: Marketed since 2022-05-19 · brand METRONIDAZOLE · ATC P01AB01 METRONIDAZOLE · form Capsule · route Oral · ingredients METRONIDAZOLE 500 MG · company Jamp pharma corporation · schedule Prescription
Metronidazole: Formulary list price $0.27 per unit (the source does not state the unit; exact figure $0.2739). What the ministry pays, not the patient.
DIN 02518767: Metronidazole
Raw flags: sec3=Y
Item: 083200002; group id 125; item number 0209; lccId None; manufacturer id JPC
Source form: Cap; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.2739; ministry $0.2739
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02518767
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100806Interchangeable products
Apo-Metronidazole · DIN 02248562 · $0.2739
Auro-Metronidazole · DIN 02470284 · $0.2739
Flagyl · DIN 01926853 · not recorded
M-Metronidazole · DIN 02519755 · $0.2739
Metronidazole · DIN 02534592 · $0.2739
PMS-Metronidazole · DIN 00783137 · $0.2739
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02518767
Shortage record checked October 6, 2026
Metronidazole · DIN 02534592 · 500 mg · capsule
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Metronidazole · DIN 02534592
Manufacturer: Sanis Health Inc.; listing date 2024-03-28
Daily cost (source): $0.8217
Health Canada: Marketed since 2023-12-21 · brand METRONIDAZOLE · ATC P01AB01 METRONIDAZOLE · form Capsule · route Oral · ingredients METRONIDAZOLE 500 MG · company Sanis health inc · schedule Prescription
Metronidazole: Formulary list price $0.27 per unit (the source does not state the unit; exact figure $0.2739). What the ministry pays, not the patient.
DIN 02534592: Metronidazole
Raw flags: sec3=Y
Item: 083200002; group id 125; item number 0209; lccId None; manufacturer id SAI
Source form: Cap; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.2739; ministry $0.2739
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02534592
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102350Interchangeable products
Apo-Metronidazole · DIN 02248562 · $0.2739
Auro-Metronidazole · DIN 02470284 · $0.2739
Flagyl · DIN 01926853 · not recorded
M-Metronidazole · DIN 02519755 · $0.2739
Metronidazole · DIN 02518767 · $0.2739
PMS-Metronidazole · DIN 00783137 · $0.2739
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02534592
Shortage record checked October 6, 2026
PMS-Metronidazole · DIN 00783137 · 500 mg · capsule
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
PMS-Metronidazole · DIN 00783137
Manufacturer: Pharmascience Inc.; listing date 1996-10-01
Daily cost (source): $0.8217
Health Canada: Marketed since 2021-04-29 · brand PMS-METRONIDAZOLE · ATC J01XD01 METRONIDAZOLE · form Capsule · route Oral · ingredients METRONIDAZOLE 500 MG · company Pharmascience inc · schedule Prescription
PMS-Metronidazole: Formulary list price $0.27 per unit (the source does not state the unit; exact figure $0.2739). What the ministry pays, not the patient.
DIN 00783137: PMS-Metronidazole
Raw flags: sec3=Y
Item: 083200002; group id 125; item number 0209; lccId None; manufacturer id PMS
Source form: Cap; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.2739; ministry $0.2739
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00783137
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9910Interchangeable products
Apo-Metronidazole · DIN 02248562 · $0.2739
Auro-Metronidazole · DIN 02470284 · $0.2739
Flagyl · DIN 01926853 · not recorded
M-Metronidazole · DIN 02519755 · $0.2739
Metronidazole · DIN 02518767 · $0.2739
Metronidazole · DIN 02534592 · $0.2739
Shortage status: resolved shortage (ended May 23, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00783137
Shortage record checked October 6, 2026
Metrogel · DIN 02092832 · 0.75% · Top Gel
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Metrogel · DIN 02092832
Manufacturer: Galderma Canada Inc; listing date 1996-10-01
Health Canada: Marketed since 1994-12-31 · brand METROGEL 0.75% · ATC D06BX01 METRONIDAZOLE · form Gel · route Topical · ingredients METRONIDAZOLE 0.75 % · company Galderma canada inc. · schedule Prescription
DIN 02092832: Metrogel
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 840416036; group id 830; item number 2020; lccId None; manufacturer id GAC
Source form: Top Gel; strength: 0.75%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02092832
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17824Interchangeable products
Taro-Metronidazole Gel · DIN 02567342 · not recorded
Shortage status: resolved shortage (ended December 21, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02092832
Shortage record checked October 6, 2026
Taro-Metronidazole Gel · DIN 02567342 · 0.75% · Top Gel
Off-Formulary Interchangeable, not an ODB benefitApproved · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Taro-Metronidazole Gel · DIN 02567342
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2026-08-31
Health Canada: Approved since 2026-04-07 · brand TARO-METRONIDAZOLE GEL · ATC D06BX01 METRONIDAZOLE · form Gel · route Topical · ingredients METRONIDAZOLE 0.75 %/W/W · company Taro pharmaceuticals inc · schedule Prescription
DIN 02567342: Taro-Metronidazole Gel
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 840416036; group id 830; item number 2020; lccId None; manufacturer id TAR
Source form: Top Gel; strength: 0.75%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $3.7845; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02567342
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106976Interchangeable products
Metrogel · DIN 02092832 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02567342
Shortage record checked October 6, 2026
Health Canada lists this DIN as Approved since April 7, 2026 — choose a marketed DIN from the same-category list.
Flagyl · PIN 01926896 · 250 mg · tablet
Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Flagyl · DIN 01926896
Manufacturer: Rhone-Poulenc Rorer-Ethical Division; listing date 2001-02-28
Daily cost (source): $0.1716
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 01926896: Flagyl
Raw flags: notABenefit=Y, sec3=Y
Item: 083200001; group id 125; item number 0210; lccId None; manufacturer id RPP
Source form: Tab; strength: 250mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01926896
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Apo-Metronidazole Tablets · DIN 00545066 · $0.0572
Mint-Metronidazole · DIN 02535807 · $0.0572
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01926896
Shortage record checked October 6, 2026
Flagyl · DIN 01926861 · 10% · Vag Cr-App
General benefit; Health Canada lists this DIN as Cancelled post market since 2024-11-26 — choose a marketed DIN from the same-category list.Discontinued November 26, 2024 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-11-26 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-11-26 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Flagyl · DIN 01926861
Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01
Health Canada: Cancelled post market since 2024-11-26 · brand FLAGYL · ATC G01AF01 METRONIDAZOLE · form Cream · route Vaginal · ingredients METRONIDAZOLE 10 % · company Sanofi-aventis canada inc · schedule Prescription
DIN 01926861: Flagyl
Raw flags: sec3=Y
Item: 840416004; group id 830; item number 2022; lccId None; manufacturer id SAV
Source form: Vag Cr-App; strength: 10%
Recorded listing: General benefit
Source prices (unrounded): $0.2740; ministry $0.2740
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01926861
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12997
Shortage status: discontinued (November 19, 2024, reported by SANOFI-AVENTIS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01926861
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 26, 2024 — choose a marketed DIN from the same-category list.
Flagyl · DIN 01926853 · 500 mg · capsule
Listed, not a benefit; Health Canada lists this DIN as Cancelled pre market since 2024-05-15 — choose a marketed DIN from the same-category list.Discontinued May 15, 2024 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled pre market since 2024-05-15 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled pre market since 2024-05-15 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Flagyl · DIN 01926853
Manufacturer: Sanofi-Aventis Canada Inc.; listing date 1996-10-01
Daily cost (source): $0.8217
Health Canada: Cancelled pre market since 2024-05-15 · brand FLAGYL · ATC P01AB01 METRONIDAZOLE · form Capsule · route Oral · ingredients METRONIDAZOLE 500 MG · company Sanofi-aventis canada inc · schedule Prescription
DIN 01926853: Flagyl
Raw flags: notABenefit=Y, sec3=Y
Item: 083200002; group id 125; item number 0209; lccId None; manufacturer id SAC
Source form: Cap; strength: 500mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01926853
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12221Interchangeable products
Apo-Metronidazole · DIN 02248562 · $0.2739
Auro-Metronidazole · DIN 02470284 · $0.2739
M-Metronidazole · DIN 02519755 · $0.2739
Metronidazole · DIN 02518767 · $0.2739
Metronidazole · DIN 02534592 · $0.2739
PMS-Metronidazole · DIN 00783137 · $0.2739
Shortage status: discontinued (January 31, 2023, reported by ODAN LABORATORIES LTD); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01926853
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled pre market since May 15, 2024 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (D06B, G01A): coverage varies; not interchangeable
Metronidazole + nystatin (Flagystatin): general benefit
Silver sulfadiazine (Flamazine): general benefit
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (08:32 Trichomonacides) and how they are covered
No products matched this class search: “08:32”.
This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code.
Search this as a medication name or DIN
Other drugs in the same formulary class (84:04:16 Other Anti-Infectives) and how they are covered
Matched class: 84:04:16 Other Anti-Infectives
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: METRONIDAZOLE & NYSTATIN, SILVER SULFADIAZINE
84:04:16 Other Anti-Infectives
· 2 products · Listed, not a benefit · strengths: 10% · Top Sol
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:04:16
1. Indications
APO-METRONIDAZOLE TABLETS (Metronidazole Tablets) is indicated for:
Bacterial Vaginosis
Metronidazole is indicated for the treatment of bacterial vaginosis.
Protozoal Infections
• Trichomonal infections in men as well as in women (protozoal infection caused by Trichomonas
vaginalis).
• Hepatic and intestinal amebiasis.
• Giardiasis.
Bacterial Infections
Treatment: Culture and susceptibility studies should be performed to determine the causative organisms
and their susceptibility to metronidazole. Based on clinical judgment and anticipated bacteriological
findings, therapy may be started while awaiting the results of these tests. However, modification of the
treatment may be necessary once these results become available.
In mixed aerobic and anaerobic infections, consideration should be given to the concomitant
administration of an antibiotic appropriate for the treatment of the aerobic component of the infection.
See 7 Warnings and Precautions, General.
Metronidazole has also been used in the treatment of a small number of cases of brain or lung infections
(some with abscesses) caused by anaerobic bacteria.
Prophylaxis: If there are signs of infections, spe…
https://pdf.hres.ca/dpd_pm/00084527.PDF
PM date: 2026-04-20
Source product: APO-METRONIDAZOLE TABLETS; DIN 00545066; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Apo-Metronidazole · DIN 02248562
Shortage status: shortage reported ended 2026-08-07 (report last updated 2026-08-07); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248562
Flagyl · DIN 01926861
Shortage status: discontinued (2024-11-19, reported by SANOFI-AVENTIS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01926861
Flagyl · DIN 01926853
Shortage status: discontinued (2023-01-31, reported by ODAN LABORATORIES LTD); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01926853
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules):
ODB 65 and over (seniors path)
Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗)
Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗)
Eligibility: Individual annual net income threshold
Program year August 1, 2026 to July 31, 2027: $25,480
This applies to a senior who:
does not have a spouse
has a married spouse with whom they no longer live in a conjugal relationship
has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗)
Eligibility: Combined annual net income requirement
Program year August 1, 2026 to July 31, 2027: $42,290
This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗)
Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗)
What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗)
Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗)
Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100.
That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year).
For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25.
Use this chart below to see what the deductible will be in your first year:
For Metrogel, Taro-Metronidazole Gel, Flagyl: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.